Cargando…

Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma

BACKGROUND: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS: A total of 14 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Takaya, Kadoya, Noriyuki, Takeda, Ken, Matsushita, Haruo, Umezawa, Rei, Sato, Kiyokazu, Kubozono, Masaki, Ito, Kengo, Ishikawa, Yojiro, Kozumi, Maiko, Takahashi, Noriyoshi, Katagiri, Yu, Onishi, Hiroshi, Jingu, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881181/
https://www.ncbi.nlm.nih.gov/pubmed/27229710
http://dx.doi.org/10.1186/s13014-016-0651-5
_version_ 1782433927742357504
author Yamamoto, Takaya
Kadoya, Noriyuki
Takeda, Ken
Matsushita, Haruo
Umezawa, Rei
Sato, Kiyokazu
Kubozono, Masaki
Ito, Kengo
Ishikawa, Yojiro
Kozumi, Maiko
Takahashi, Noriyoshi
Katagiri, Yu
Onishi, Hiroshi
Jingu, Keiichi
author_facet Yamamoto, Takaya
Kadoya, Noriyuki
Takeda, Ken
Matsushita, Haruo
Umezawa, Rei
Sato, Kiyokazu
Kubozono, Masaki
Ito, Kengo
Ishikawa, Yojiro
Kozumi, Maiko
Takahashi, Noriyoshi
Katagiri, Yu
Onishi, Hiroshi
Jingu, Keiichi
author_sort Yamamoto, Takaya
collection PubMed
description BACKGROUND: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS: A total of 14 patients (11 males, 3 females) who received SBRT for RCC at Tohoku University Hospital between April 2010 and February 2014 were analyzed. The median serum creatinine level was 1.1 mg/dl and two patients had a single kidney. Nine patients were implanted with fiducial markers. The median tumor diameter was 30 mm. SBRT was delivered at 70 Gy in 10 fractions for 7 tumors, at 60 Gy in 10 fractions for 2 tumors, and at 50 Gy in 10 fractions for 5 tumors with 6 and/or 15 MV X-ray using 5 to 8 multi-static beams. Renal atrophy was assessed using post-SBRT CT images after 12–24 months intervals. Correlations were examined by Spearman rank correlation analysis. Differences between two groups were evaluated by the Mann-Whitney test, and pairwise comparisons were made by the Wilcoxon signed-rank test. RESULTS: The median tumor volume shrunk from 14.8 cc to 10.6 cc (p = 0.12), and the median irradiated kidney volume changed from 160.4 cc to 137.1 cc (p < .01). The median peak creatinine level was 1.6 mg/dl after treatment (p < .01). Percentage volumes of the irradiated kidney receiving at least 10 Gy (V(10), p = 0.03), V(20) (p < .01), V(30)(p < .01), V(40) (p = 0.01), mean irradiated kidney dose (p < .01), and magnitude of overlap between PTV and kidney volume (p = 0.03) were significantly correlated with post-treatment irradiated kidney volume in percent, and V(20)-V(30) had strong correlation (r < −0.70, p < .01). Patients with implanted fiducial markers showed a significantly lower ratio of renal atrophy (p = 0.02). CONCLUSIONS: Significant renal atrophic change was observed. Dose distribution of SBRT at 20–30 Gy had a strong correlation with renal atrophy when irradiation was performed in 10 fractions.
format Online
Article
Text
id pubmed-4881181
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48811812016-05-27 Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma Yamamoto, Takaya Kadoya, Noriyuki Takeda, Ken Matsushita, Haruo Umezawa, Rei Sato, Kiyokazu Kubozono, Masaki Ito, Kengo Ishikawa, Yojiro Kozumi, Maiko Takahashi, Noriyoshi Katagiri, Yu Onishi, Hiroshi Jingu, Keiichi Radiat Oncol Research BACKGROUND: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS: A total of 14 patients (11 males, 3 females) who received SBRT for RCC at Tohoku University Hospital between April 2010 and February 2014 were analyzed. The median serum creatinine level was 1.1 mg/dl and two patients had a single kidney. Nine patients were implanted with fiducial markers. The median tumor diameter was 30 mm. SBRT was delivered at 70 Gy in 10 fractions for 7 tumors, at 60 Gy in 10 fractions for 2 tumors, and at 50 Gy in 10 fractions for 5 tumors with 6 and/or 15 MV X-ray using 5 to 8 multi-static beams. Renal atrophy was assessed using post-SBRT CT images after 12–24 months intervals. Correlations were examined by Spearman rank correlation analysis. Differences between two groups were evaluated by the Mann-Whitney test, and pairwise comparisons were made by the Wilcoxon signed-rank test. RESULTS: The median tumor volume shrunk from 14.8 cc to 10.6 cc (p = 0.12), and the median irradiated kidney volume changed from 160.4 cc to 137.1 cc (p < .01). The median peak creatinine level was 1.6 mg/dl after treatment (p < .01). Percentage volumes of the irradiated kidney receiving at least 10 Gy (V(10), p = 0.03), V(20) (p < .01), V(30)(p < .01), V(40) (p = 0.01), mean irradiated kidney dose (p < .01), and magnitude of overlap between PTV and kidney volume (p = 0.03) were significantly correlated with post-treatment irradiated kidney volume in percent, and V(20)-V(30) had strong correlation (r < −0.70, p < .01). Patients with implanted fiducial markers showed a significantly lower ratio of renal atrophy (p = 0.02). CONCLUSIONS: Significant renal atrophic change was observed. Dose distribution of SBRT at 20–30 Gy had a strong correlation with renal atrophy when irradiation was performed in 10 fractions. BioMed Central 2016-05-26 /pmc/articles/PMC4881181/ /pubmed/27229710 http://dx.doi.org/10.1186/s13014-016-0651-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yamamoto, Takaya
Kadoya, Noriyuki
Takeda, Ken
Matsushita, Haruo
Umezawa, Rei
Sato, Kiyokazu
Kubozono, Masaki
Ito, Kengo
Ishikawa, Yojiro
Kozumi, Maiko
Takahashi, Noriyoshi
Katagiri, Yu
Onishi, Hiroshi
Jingu, Keiichi
Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
title Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
title_full Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
title_fullStr Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
title_full_unstemmed Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
title_short Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
title_sort renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881181/
https://www.ncbi.nlm.nih.gov/pubmed/27229710
http://dx.doi.org/10.1186/s13014-016-0651-5
work_keys_str_mv AT yamamototakaya renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT kadoyanoriyuki renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT takedaken renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT matsushitaharuo renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT umezawarei renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT satokiyokazu renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT kubozonomasaki renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT itokengo renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT ishikawayojiro renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT kozumimaiko renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT takahashinoriyoshi renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT katagiriyu renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT onishihiroshi renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma
AT jingukeiichi renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma